The UK’s proposal to give under-30s other vaccines shouldn’t be too disruptive, but in Europe, greater restrictions look likely.
Academic rigor, journalistic flair
Articles on EMA
Displaying all articles
Australia is still aiming to start vaccinating high-risk groups from March. Why the delay?
American companies still face enormous uncertainty about how they’ll be doing business in the UK and EU in the coming years, particularly as the April 12 Brexit deadline draws closer.
Gone are the good old days when medicines had simple, easy to pronounce names such as aspirin, paracetamol and morphine. Nowadays pharmaceutical companies almost seem to revel in giving drugs names that…
The announcement that controversial mining billionaire Gina Rinehart is to use new Enterprise Migration Agreements to employ 1715 foreign construction workers on her $9.5 billion Roy Hill iron ore project…
Top contributors
-
Honorary Professor of Demography, Centre for Health Policy, The University of Melbourne
-
Professor in Clinical Pharmacy and Drug Safety, University of Birmingham
-
Associate Professor of the School of Pharmacy, University of Sydney
-
Honorary Lecturer, School of Pharmacy, Charles Perkins Centre, University of Sydney
-
Associate professor, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Clinical Associate Professor of Business Economics, Indiana University
-
PhD Candidate and Pharmacist, University of Sydney
